Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) Files An 8-K Other EventsItem 8.01. Other Events.
As previously reported by the Company, the Company’s voluntary withdrawal from listing on Nasdaq constituted a “Fundamental Change” to the indenture (“Indenture”) relating to the Company’s Convertible Senior Notes (the “Notes”) that were issued in August, 2014 and are otherwise due in August, 2017. The Company was obligated to make an offer to repurchase the Notes in accordance with the terms of the Indenture within a period of 20 business days following this change. Accordingly, the Company was obligated to deliver the offer by January 19, 2017. If the Company’s offer is accepted, the Company will be obligated to execute the repurchase of the Notes by March 10, 2017. However, the Company is in active negotiations with interested third parties and the Holder of the Notes relating to a potential negotiated resolution in lieu of the Company repurchasing the Notes to the Indenture provisions.
In accordance with the Indenture, on January 19, 2017, the Company delivered a fundamental change notice (the “Notice”) to theHolder of the Notes. The Notice indicates that the Company is offering to repurchase the Notes at a fundamental change repurchase price (the “Fundamental Change Repurchase Price”) equal to 50% of the principal amount of the Notes, plus any accrued and unpaid interest on the Notes up to, but not including, March 10, 2017 (the “Fundamental Change Repurchase Offer”). The full amount of interest for the full term of the Notes was escrowed at the time the Notes were entered into, and the funds for all interest amounts not yet paid remain in escrow.
The Notice also indicated that: (i) the Company ceased to be quoted on the Nasdaq Stock Market, which constituted a Fundamental Change and Make-Whole Fundamental Change under the Indenture, effective as of the open of trading on December 19, 2016; (ii) the anticipated fundamental change repurchase date for the Fundamental Change Repurchase Offer is March 10, 2017; (ii) the Paying Agent and Conversion Agent for the Notes is The Bank of New York Mellon, whose address is 101 Barclay St – 7W, New York NY 10286; (iii) the holder of the Notes must validly surrender the Notes and deliver a Fundamental Change Repurchase Notice to the Paying Agent Prior to 5:00 p.m. on March 9, 2017 in order to participate in the Fundamental Change Repurchase Offer; (iv) the holder may withdraw any valid submission of Notes by delivering to the Paying Agent, prior to 5:00 p.m. (New York City time) on March 9, 2017, a written notice of withdrawal specifying (a) the certificate number, if any, of the Notes in respect of which such notice of withdrawal is being submitted, (b) the principal amount of the Notes in respect of which such notice of withdrawal is being submitted and (c) the principal amount of the Notes which still remain subject to the original Fundamental Change Repurchase Notice; and (v) that the holder will retain its conversion rights with respect to the Notes but must withdraw any its request to have the Notes repurchased before it may convert. The current Conversion Rate for the Securities is 151.4142 shares of Company common stock per $1,000 principal amount of Notes.
The Company is in active discussions with the Holder and third parties concerning a possible mutually agreeable negotiated transaction in lieu of the Company repurchasing the Notes at the Fundamental Change Repurchase Price. However, at the current time, no definitive agreement with respect to an alternative transaction is yet in place, and there can be no assurance that such negotiations will be successful. In addition, there can be no assurance that, if an alternative resolution is not reached, the Company will be able to repurchase the Notes in accordance with the Notice by March 10, 2017.
About Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO)
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company’s lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company’s platform technology, DCVax, uses activated dendritic cells to mobilize a patient’s own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer. Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) Recent Trading Information
Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) closed its last trading session down -0.035 at 0.430 with 1,123,320 shares trading hands.